Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving dru...
Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade. These trials have led to the introduction of four main drug classes into the 2021 ESC guideline, namely angiotensin-receptor neprilysin inhibitors/angiotensin-converting-enzyme inhibitors, beta-bl...
Alternative Titles
Full title
Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10403394
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10403394
Other Identifiers
ISSN
1573-7322,1382-4147
E-ISSN
1573-7322
DOI
10.1007/s10741-023-10325-2
